Literature DB >> 19115257

Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis.

Madhuchhanda Roy1, Dario Marchetti.   

Abstract

Heparan sulfate (HS) proteoglycans are essential components of the cell-surface and extracellular matrix (ECM) which provide structural integrity and act as storage depots for growth factors and chemokines, through their HS side chains. Heparanase (HPSE) is the only mammalian endoglycosidase known that cleaves HS, thus contributing to matrix degradation and cell invasion. The enzyme acts as an endo-beta-D-glucuronidase resulting in HS fragments of discrete molecular weight size. Cell-surface HS is known to inhibit or stimulate tumorigenesis depending upon size and composition. We hypothesized that HPSE contributes to melanoma metastasis by generating bioactive HS from the cell-surface to facilitate biological activities of tumor cells as well as tumor microenvironment. We removed cell-surface HS from melanoma (B16B15b) by HPSE treatment and resulting fragments were isolated. Purified cell-surface HS stimulated in vitro B16B15b cell migration but not proliferation, and importantly, enhanced in vivo angiogenesis. Furthermore, melanoma cell-surface HS did not affect in vitro endothelioma cell (b.End3) migration. Our results provide direct evidence that, in addition to remodeling ECM and releasing growth factors and chemokines, HPSE contributes to aggressive phenotype of melanoma by releasing bioactive cell-surface HS fragments which can stimulate melanoma cell migration in vitro and angiogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19115257      PMCID: PMC2736788          DOI: 10.1002/jcb.22005

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  57 in total

1.  Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.

Authors:  Ilana Doweck; Victoria Kaplan-Cohen; Inna Naroditsky; Edmond Sabo; Neta Ilan; Israel Vlodavsky
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

2.  HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.

Authors:  Keishi Narita; Julie Staub; Jeremy Chien; Kristy Meyer; Maret Bauer; Andreas Friedl; Sundaram Ramakrishnan; Viji Shridhar
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 3.  Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.

Authors:  Ralph D Sanderson; Yang Yang; Thomas Kelly; Veronica MacLeod; Yuemeng Dai; Allison Theus
Journal:  J Cell Biochem       Date:  2005-12-01       Impact factor: 4.429

4.  Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1.

Authors:  Andrew C Lake; Roger Vassy; Mélanie Di Benedetto; Damien Lavigne; Catherine Le Visage; Gérard Y Perret; Didier Letourneur
Journal:  J Biol Chem       Date:  2006-10-06       Impact factor: 5.157

5.  HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo.

Authors:  Yuemeng Dai; Yang Yang; Veronica MacLeod; Xinping Yue; Alan C Rapraeger; Zachary Shriver; Ganesh Venkataraman; Ram Sasisekharan; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2005-09-27       Impact factor: 5.157

Review 6.  Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Authors:  Neta Ilan; Michael Elkin; Israel Vlodavsky
Journal:  Int J Biochem Cell Biol       Date:  2006-07-06       Impact factor: 5.085

7.  In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation.

Authors:  Xiulong Xu; Geetha Rao; Roderick M Quiros; Anthony W Kim; Hua-Quan Miao; Gregory J Brunn; Jeffrey L Platt; Paolo Gattuso; Richard A Prinz
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

8.  FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.

Authors:  Jane Reiland; Doty Kempf; Madhuchhanda Roy; Yvonne Denkins; Dario Marchetti
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

Review 9.  Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Authors:  Girolamo Ranieri; Rosa Patruno; Eustachio Ruggieri; Severino Montemurro; Paolo Valerio; Domenico Ribatti
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 10.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

View more
  33 in total

1.  Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.

Authors:  Vy M Tran; Anna Wade; Andrew McKinney; Katharine Chen; Olle R Lindberg; Jane R Engler; Anders I Persson; Joanna J Phillips
Journal:  Mol Cancer Res       Date:  2017-08-04       Impact factor: 5.852

Review 2.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

3.  Targeted silencing of heparanase gene by small interfering RNA inhibits invasiveness and metastasis of osteosarcoma cells.

Authors:  Lei Fan; Qiang Wu; Xiaojuan Xing; Yudong Liu; Zengwu Shao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

4.  Involvement of Ext1 and heparanase in migration of mouse FBJ osteosarcoma cells.

Authors:  Yinan Wang; XiaoYan Yang; Sadako Yamagata; Tatsuya Yamagata; Toshinori Sato
Journal:  Mol Cell Biochem       Date:  2012-10-10       Impact factor: 3.396

Review 5.  Molecular functions of syndecan-1 in disease.

Authors:  Yvonne Hui-Fang Teng; Rafael S Aquino; Pyong Woo Park
Journal:  Matrix Biol       Date:  2011-10-18       Impact factor: 11.583

6.  Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.

Authors:  Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 7.  Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.

Authors:  Imola Wilhelm; Csilla Fazakas; Kinga Molnár; Attila G Végh; János Haskó; István A Krizbai
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-18       Impact factor: 6.200

8.  Heparanase expression correlates with poor survival in oral mucosal melanoma.

Authors:  Xin Wang; Weiwei Wen; Heming Wu; Yi Chen; Guoxin Ren; Wei Guo
Journal:  Med Oncol       Date:  2013-06-21       Impact factor: 3.064

9.  Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.

Authors:  Michael P O'Connell; Jennifer L Fiori; Emily K Kershner; Brittany P Frank; Fred E Indig; Dennis D Taub; Keith S Hoek; Ashani T Weeraratna
Journal:  J Biol Chem       Date:  2009-08-20       Impact factor: 5.157

10.  Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.

Authors:  Anurag Purushothaman; Toru Uyama; Fumi Kobayashi; Shuhei Yamada; Kazuyuki Sugahara; Alan C Rapraeger; Ralph D Sanderson
Journal:  Blood       Date:  2010-01-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.